Show simple item record

dc.contributor.advisorRitter, Thomas
dc.contributor.advisorRyan, Aideen E.
dc.contributor.authorLohan, Paul
dc.date.accessioned2016-05-11T14:33:42Z
dc.date.available2016-05-11T14:33:42Z
dc.date.issued2016-05-11
dc.identifier.urihttp://hdl.handle.net/10379/5772
dc.description.abstractOsteoarthritis is a debilitating multi-factorial joint disease which currently has no cure. Due to the significant immune cell mediated component in this disease a therapy which can modulate this inflammation and promote cartilage healing is urgently required. An allogeneic cell therapy could be particularly beneficial in OA. One such allogeneic cell is the mesenchymal stem cell (MSC). MSC, in addition to their chondrogenic differentiation capacity, possess potent immunomodulatory capabilities in the undifferentiated state. The first part of this work focused on the immune properties of allogeneic MSC after differentiation to a chondrogenic lineage. The work found that after chondrogenic differentiation MSC upregulate immunogenic cell surface molecules such as MHCI, MHCII, CD80 and CD86 and are functionally more immunogenic in vitro. Additionally these cells were found to lose their ability to modulate allogeneic lymphocyte proliferation in in vitro co-culture assays, possibly due to the loss of PGE2 and nitric oxide secretion. In vivo, it was shown that chondrogenically differentiated MSC, implanted subcutaneously, elicit significantly more infiltration of mononuclear phagocytes than their undifferentiated counterparts. Allogeneic differentiated MSC also resulted in higher memory T cell and allo-antibody responses compared to undifferentiated MSC, highlighting their immunogenicity. An alternative cell type for allogeneic cell therapy in OA is the chondrocyte itself. To test the immune properties of allogeneic chondrocytes, cartilage was excised and chondrocytes cultured from it in vitro. These cells were termed culture expanded primary chondrocytes (CEPC). In vitro CEPC were shown to be non-immunogenic, eliciting equivalent allogeneic T cell proliferation as undifferentiated MSC. This immunogenicity was not affected by culturing the cells in hypoxic conditions or exposing the cells to an inflammatory environment in vitro. Additionally CEPC could modulate both T cell and macrophage activity in vitro. This T cell immunomodulatory capacity was shown to be nitric oxide dependent. In summary, allogeneic chondrogenically differentiated MSC lose their immunomodulatory ability and become more immunogenic, while allogeneic CEPC are not immunogenic and have potent immunomodulatory activity in vitro.en_IE
dc.subjectOsteoarthritisen_IE
dc.subjectMesenchymal Stem Cellen_IE
dc.subjectCell therapyen_IE
dc.subjectAllogeneicen_IE
dc.subjectChondrocyteen_IE
dc.subjectCartilageen_IE
dc.subjectRegenerative Medicineen_IE
dc.subjectMedicineen_IE
dc.titleAllogeneic cell therapy for osteoarthritisen_IE
dc.typeThesisen_IE
dc.contributor.funderEuropean Union FP7 BMERM programmeen_IE
dc.local.noteOsteoarthritis a debilitating disease, which has a significant immune mediated component and no cure. This work profiled the immune properties of allogeneic differentiated mesenchymal stem cells (dMSC) and primary chondrocytes (CEPC) as potential therapeutics for osteoarthritis. It was found that while dMSC lose their immunomodulatory ability, CEPC are capable of modulating an inflammatory response.en_IE
dc.local.finalYesen_IE
nui.item.downloads875


Files in this item

Attribution-NonCommercial-NoDerivs 3.0 Ireland
This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. Please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.

The following license files are associated with this item:

Thumbnail

This item appears in the following Collection(s)

Show simple item record